Arthur Klausner
Executive Chairman, Concarlo Therapeutics
Life Sciences and Venture Capital Consultant

An experienced life sciences executive and investor, Arthur Klausner currently serves as Executive Chairman of Concarlo Therapeutics (oncology) and is the former CEO of Goldilocks Therapeutics (nephrology), Gem Pharmaceuticals (oncology), and Jade Therapeutics (ophthalmology). He currently serves as a board member of Monopar Therapeutics,Beryl Therapeutics, and Gem Pharmaceuticals.

Prior to his operating roles, Arthur spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. During that time, he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies. Klausner has been a board member at Santarus (IPO in 2004), X-Ceptor (acquired by Exelixis in 2004), Orexigen (IPO in 2007), and Syndax Pharmaceuticals (IPO in 2016), and a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005) and Cerexa (acquired by Forest Laboratories in 2007), among others. He currently serves on the Board of Directors of Goldilocks Therapeutics, Monopar Therapeutics, and AmyriAD Therapeutics, as well as on Advisory Boards for the New York University Innovation Venture Fund and 1 st Pitch Life Science.

Klausner began his venture capital career after earning an M.B.A. at the Stanford University Graduate School of Business. While attending business school, he completed summer internships emphasizing corporate planning and market research functions at ImClone Systems and Neurogen, two startup biopharmaceutical companies that subsequently went public. Previously, Klausner had spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology. He has also performed consulting projects for the U.S. Office of Technology Assessment, Arthur D. Little Decision Resources, and a range of pharmaceutical and biotechnology companies. His undergraduate degree in Biology is from Princeton University.